CN107312108A - A kind of preparation method and applications of lentinan chromic compound - Google Patents
A kind of preparation method and applications of lentinan chromic compound Download PDFInfo
- Publication number
- CN107312108A CN107312108A CN201710623831.8A CN201710623831A CN107312108A CN 107312108 A CN107312108 A CN 107312108A CN 201710623831 A CN201710623831 A CN 201710623831A CN 107312108 A CN107312108 A CN 107312108A
- Authority
- CN
- China
- Prior art keywords
- lentinan
- chromic compound
- volume
- ethanol
- centrifugation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001491 Lentinan Polymers 0.000 title claims abstract description 50
- 229940115286 lentinan Drugs 0.000 title claims abstract description 48
- 150000001875 compounds Chemical class 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000011651 chromium Substances 0.000 claims abstract description 56
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 28
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 11
- 238000000746 purification Methods 0.000 claims abstract description 9
- 239000002955 immunomodulating agent Substances 0.000 claims abstract description 5
- 229940121354 immunomodulator Drugs 0.000 claims abstract description 5
- 230000002584 immunomodulator Effects 0.000 claims abstract description 5
- 230000003647 oxidation Effects 0.000 claims abstract description 3
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 11
- 238000005119 centrifugation Methods 0.000 claims description 10
- 235000019441 ethanol Nutrition 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 7
- 229910021556 Chromium(III) chloride Inorganic materials 0.000 claims description 6
- 239000011636 chromium(III) chloride Substances 0.000 claims description 6
- 235000009508 confectionery Nutrition 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 5
- 239000012043 crude product Substances 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 239000008236 heating water Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000013049 sediment Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- AZHSSKPUVBVXLK-UHFFFAOYSA-N ethane-1,1-diol Chemical compound CC(O)O AZHSSKPUVBVXLK-UHFFFAOYSA-N 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 238000002390 rotary evaporation Methods 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 abstract description 11
- 229920001282 polysaccharide Polymers 0.000 abstract description 10
- 239000005017 polysaccharide Substances 0.000 abstract description 10
- 230000036039 immunity Effects 0.000 abstract description 7
- 235000013402 health food Nutrition 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 5
- 238000004458 analytical method Methods 0.000 abstract description 4
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 3
- 238000000870 ultraviolet spectroscopy Methods 0.000 abstract description 3
- 239000007795 chemical reaction product Substances 0.000 abstract description 2
- 238000010668 complexation reaction Methods 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 210000002966 serum Anatomy 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 11
- 102000016938 Catalase Human genes 0.000 description 10
- 108010053835 Catalase Proteins 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 10
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 7
- 102100033468 Lysozyme C Human genes 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000013522 chelant Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 6
- 102000016918 Complement C3 Human genes 0.000 description 5
- 108010028780 Complement C3 Proteins 0.000 description 5
- 229910021645 metal ion Inorganic materials 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 108010014251 Muramidase Proteins 0.000 description 4
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 4
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 229960000274 lysozyme Drugs 0.000 description 4
- 239000004325 lysozyme Substances 0.000 description 4
- 235000010335 lysozyme Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 2
- 239000011609 ammonium molybdate Substances 0.000 description 2
- 235000018660 ammonium molybdate Nutrition 0.000 description 2
- 229940010552 ammonium molybdate Drugs 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000000091 immunopotentiator Effects 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 241000222501 Agaricaceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 241000040710 Chela Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 241000222418 Lentinus Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical group O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000001455 metallic ions Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Sustainable Development (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of preparation method and applications of lentinan chromic compound, by lentinan after purification, complexation reaction is formed the lentinan chromic compound under certain condition with chromium.Reaction product carries out coordination analysis, it was demonstrated that polysaccharide and Cr through isolating and purifying using ultraviolet visible spectrometry, infra-red sepectrometry3+Form complex.Active animal experiment shows that there is lentinan chromic compound significantly drop to improve immunity and anti-oxidation function.It thus can be used for preparing in immunomodulator, oxidation resistant medicine and health food.
Description
Technical field
The invention belongs to field of medicaments, and in particular to a kind of preparation method and applications of lentinan-chromic compound.
Background technology
Immunity is the defense mechanism of human body itself, is any foreign matter of human bioequivalence and the external entrance of elimination（It is viral, thin
Bacterium etc.）；Handle aging, damage, death, the own cells of denaturation and identification and processing vivo mutations cell and virus infection is thin
The ability of born of the same parents.Immunology Today thinks that immunity is human bioequivalence and the physiological reaction for excluding " dissident ".Nearly all disease
Generation is all relevant with autoimmunity decline, or because disease causes immunity of organisms to decline, so improving autoimmunity is
The basic guarantee of health.Thus immunological regulation or immunopotentiator have acted what is held the balance to the health of the mankind.
Lentinan（Lentinan abbreviations LNT）It is to extract to obtain from the natural mushroom fruiting body of Agaricaceae Lentinus
A kind of β (1-3）Glucan.It is the material that a class has the pharmacological activity such as antiviral, antitumor, regulation body immunity,
The multiple efficacies such as also hypoglycemic, anti-oxidant.Especially it has significant, unique antitumor activity, such as thin to chronic grain
The effect that born of the same parents' leukaemia, stomach cancer, snuff cancer, the carcinoma of the rectum and breast cancer etc. have inhibitory action and prevents Post operation from shifting, it is adaptable to
Physical recovery, is to be currently known stronger immunopotentiator, and mitigate the toxic side effect of radiation and chemotherapy after being ill.In addition, mushroom
Polysaccharide still treats various hepatitis, the good medicine of particularly chronic migration hepatitis.At present, by Jinting Pharmaceutical Co., Ltd.
The lentinus edodes polysaccharide injecta of Meifeng Pharmaceutical Factory Fuzhou City's production, for the putting of chronic type b metastatic hepatitis and tumor in digestive tract, changes
Adjuvant is treated, has very high curative effect in clinic.But, although lentinan has the biological function of brilliance, so far polysaccharide
The auxiliary treatment stage is only resided within as medicine.Research also found that the pharmacological activity of polysaccharide in vivo more passes through glycolipid, sugared egg
White combination is worked in the form of metallo-chelate.
Many trace elements such as transition metal（Such as Cu, Cr）, nonmetalloid such as selenium etc., they have very high battalion
Health care and pharmacological activity are supported, such as chromium is one kind trace element needed by human, can improve the immunologic function of animal, so as to improve
Its resistance against diseases.But these have its micro- simple substance or free metal ion of bioactivity（Such as Cu2+, Cr3+）Inhale
Yield is low, and toxicity is larger, and its physiologically active will can just be worked by suitable ligand formation complex.Usual organic ligand with
Not only its physicochemical property is varied widely after metal ion formation chelate, and great variety can also occur for bioactivity.It is not
But it can more preferably play the function of original part and metal ion, it is also possible to produce synergy.Such as many feature organic matter-gold
Metal complex cancer therapy drug, antibiotic-metallo-chelate antimicrobial and feature organic matter-minor metallic element complex are protected
The extensive use of health food has been proved this point.If in consideration of it, under suitable conditions by polysaccharide and active metallic ion chela
Close, form stable chelate, not only the reduction of its toxicity, absorptivity are improved, and very big improvement will also occur for its physiological property,
Multifunctional matter will be turned into.
If in consideration of it, by lentinan and metal ion-chelant, very big improvement will also occur for its performance.Due to many
Sugar has abundant hydroxyl, is good part, and it is good central ion that Cr, which is free 3d tracks, as long as condition properly will shape
Into stable chelate.This project chelates to form lentinan-Cr chelates with lentinan and Cr, study its coordination structure and
Anti-oxidant, immunoregulatory activity effect, experiment shows that the anti-oxidant of lentinan-chromic compound, immunoregulatory activity are notable
Higher than inorganic chromium and lentinan, thus it can be used for preparing in anti-oxidant, immunomodulator medicine and health food.
The content of the invention
It is an object of the invention to provide a kind of preparation method and applications of lentinan-chromic compound.
Lentinan-chromic compound of the present invention be by mushroom Thick many candies by Svage methods carry out deproteinized purification,
By the lentinan after purification in different temperature, different pH value, different reaction time and Cr3+Complexation reaction, is probed into most
Good technique.Lentinan-chromium compound detects that lentinan is coordinated to be formed with chromium through infra-red sepectrometry, ultravioletvisible spectroscopy
Complex compound；Active animal experiment shows that lentinan-chromic compound has significantly anti-oxidant and raising immunity function.Thus
Available for preparing in anti-oxidant, immunomodulator medicine and health food.
The preparation method and applications of lentinan-chromic compound of the present invention, comprise the following steps：
（1）Mushroom Thick many candies obtain refined lentinan using Svage method deproteinizeds method.
（2）Lentinan and Cr after purification3+Lentinan-Cr complexs are synthesized under weak basic condition；
（3）Lentinan-chromic compound is dialysed through bag filter, concentrated frozen is dried, the lentinan-Cr obtained after purification matches somebody with somebody
Compound, the wherein content of Cr elements are 6.27wt%.
（4）Coordination analysis is carried out to reaction product using ultravioletvisible spectroscopy, infra-red sepectrometry, it was demonstrated that polysaccharide and Cr3+
Form complex.
Lentinan-chromic compound has been carried out to the research of mouse antioxidation activity, has as a result shown that lentinan-chromium coordinates
Thing has the antioxidation activity higher than inorganic chromium and lentinan.
Lentinan-chromic compound has been carried out to the research of mouse immune regulation activity, has as a result shown that lentinan-chromium is matched somebody with somebody
Compound has stronger immunoregulation effect than lentinan.
Beneficial effects of the present invention：1st, lentinan-chromic compound not yet has synthesis and the immune work(of anti-oxidant, raising at present
The activity research report of energy, the present invention can be used for preparing in anti-oxidant, immunomodulator medicine and health food.This newcooperative medical system
Its great advantage of compound is that lentinan is natural extracts, can medicine-food two-purpose；And chromium is normal carbohydrate and fat
Trace element necessary to class metabolism, trivalent chromium participates in glycometabolism, is to maintain the glucose tolerance of animal and human normal can not
The element lacked, while having stronger raising immune again and anti-stress effect.The two not only can more preferably send out after forming chelate
The function of original part and metal ion is waved, part and metal ion can also produce synergy, significantly improve the antioxygen of body
Change ability and immunoregulation capability, and nontoxic pair is small, has no adverse reaction, and can be used for a long time；2nd, it is anti-oxidant, immune available for preparing
The medicine of conditioning agent, it can also be used to prepare health food；3rd, raw material is easy to get, and complex preparation technology is simple, inexpensive, producer
Just, Development volue is high.
Brief description of the drawings
Fig. 1 is lentinan infrared absorption pattern；
Fig. 2 is lentinan-chromic compound infrared spectrogram；
Fig. 3 is CrCl3•6H2O UV-visible absorption spectrums；
Fig. 4 is lentinan-chromic compound UV-visible absorption spectrum；
Fig. 5 is mouse spleen index contrast figure；
Fig. 6 is SOD vigor comparison diagrams in mice serum；
Fig. 7 is LDH vigor comparison diagrams in mice serum；
Fig. 8 is CAT vigor comparison diagrams in mice serum；
Fig. 9 is LZM content balance figures in mice serum.
Embodiment
Embodiment 1
The purifying of 1 lentinan
The thick lentinans of 10.0g are weighed in 800mL distilled water, 80 DEG C of heating water baths simultaneously instill 2 mol L of a few drops-1NaOH is molten
Liquid, controls pH=8.0 of solution or so.Stirring, accelerates the dissolving of Thick many candies.Then by volume（Thick many candies liquid：Chloroform：Positive fourth
Alcohol=25：5:1）Chloroform and n-butanol are added, quick stir about 20min is stood, and point liquid removes sub-cloud organic reagent, is then centrifuged for
Remove intermediate protein solid.Again by volume（Thick many candies liquid：Chloroform：N-butanol=25：5:1）Add chloroform and n-butanol, weight
Operated more than multiple, until middle produce without white solid.Rotary evaporation concentration adds 2-3 times of volume about to the 1/5 of original volume
95wt% ethanol alcohol precipitations, centrifugation, the lentinan for being freeze-dried after purification.Lentinan after purification is flaxen sponge
Shape material, it is more soluble in water.
The preparation of 2 lentinans-chromic compound
The lentinan that 1.6g is purified and dried is weighed, is dissolved by heating in 250mL80 DEG C of distilled water.In 80 DEG C of water bath conditions
Under 2 mol L are slowly added dropwise-1CrCl3•6H2O solution（About 600 μ L, equivalent to 0.32gCrCl3•6H2O）With 2 mol L-1
NaOH solution and be stirred continuously, control pH value of solution=9.0 or so.Until occurring flocculent deposit in solution, stop that CrCl is added dropwise3•
6H2O and NaOH solution, continue to keep 80 DEG C of heating water bath 1h.3500r/min centrifugations 10min takes supernatant, adds 2-3 times of body
Precipitation is collected by centrifugation in the 95wt% ethanol of accumulated amount, cooling and standings.Stirred respectively with 95wt% ethanol, absolute ethyl alcohol, acetone, absolute ether
Mix to swing and wash sediment, be collected by centrifugation and precipitate and be dried under reduced pressure, obtain lentinan-chromic compound crude product.
Lentinan-chromic compound crude product is dissolved in appropriate distilled water, is fitted into pretreated bag filter and is clamped,
Added water in 2L large beakers, magnetic agitation is dialysed 2-3 days, a water is changed in centre at regular intervals, changes water frequency first quick and back slow, thoroughly
After analysis terminates, concentration adds 2-3 times of volume 95wt% ethanol, is collected by centrifugation precipitation, and precipitation uses 95wt% ethanol respectively, anhydrous
Ethanol, acetone, absolute ether washing, are dried under reduced pressure, obtain lentinan-chromic compound fine work, the content of wherein Cr elements is
6.27wt%。
3 lentinans-chromic compound spectrum analysis
3.1 infrared spectrum analysis
Respectively will thorough dried lentinan and its Cr complex and KBr in mass ratio 1：（100-200）Ratio mix
Tabletting after even, grinding, is scanned with infrared spectrometer, obtains both infrared spectrums.
Contrasted from infared spectrum Fig. 1 and Fig. 2, lentinan chromic compound is in wavelength 3400cm- 1The hydroxyl of left and right
Stretching vibration (νO-H) the contrast of hydrogen bond association peak intensity and corresponding polysaccharide weakened, and absworption peak frequency is to high wave number direction
It is mobile（From 3407cm-1 To 3446cm-1）, it is probably because trivalent chromic ion and hydroxyl oxygen atom there occurs that coordination is anti-to speculate this
Should, cause hydroxyl to form intermolecular and intramolecular hydrogen bond reduced capability, coordination makes the bond force constant for the former chemical bond to form hydrogen bond
Rise, Infra-red Absorption Frequency shifts to high wave number.The infrared absorption peak of lentinan chromic compound is can also be seen that by Fig. 1 and Fig. 2
Compared with before lentinan coordination, significant change does not occur for the characteristic absorption peak of skeleton, so speculating trivalent chromic ion and perfume
The hydroxyl of mushroom polysaccharide forms coordinate bond.
3.2 ultraviolet spectral analysis
By lentinan-chromium complex and CrCl3•6H2O is configured to 0.01 mol L-1The aqueous solution, use ultraviolet-visible
At spectrometer scanning wavelength 200-800nm, reference is made of distilled water, sweep speed is " fast ", and the sampling interval is 1nm.Both
Ultraviolet spectra.
Contrasted from Fig. 3 and Fig. 4, the maximum absorption wavelength of the trivalent chromium in lentinan-Cr complexs relative to
CrCl3•6H2Chromium has obvious Red Shift Phenomena in O（From 410 cm- 1— 435 cm- 1, from 575 cm- 1—590 cm- 1）.I
Know, as the lentinan of part in itself without UV absorption, the interference of polysaccharide can be excluded, therefore speculate that red shift is due to
CrCl3•6H2The d orbital electron of trivalent chromic ion in O solution is influenceed generation electron transition to make absorption band by ligand
Produce Red Shift Phenomena.
The bioactivity of 4 lentinans-chromic compound
4.1 animal packets and processing
After mouse buys conventinal breeding three days, physiological saline group, lentinan group, inorganic chromium group, lentinan-Cr is set to coordinate
The high, medium and low dosage group of thing, totally six groups, every group of 10 mouse.Lentinan group dosage is 100mg/kg, and inorganic chromium group is given
The μ g/kg of dose 10, lentinan chromium high dose group dosage is 200mg/kg, and middle dose group dosage is 100mg/kg, low dose
Amount group dosage is 50mg/kg.Daily gastric infusion 1 time, each 0.2ml, the fasting 12h again of successive administration 12 days.
4.2 activity index are determined
Mouse after administration is all weighed and record data.Extract eyeball of mouse and take blood, 4000r/min centrifuges 10 minutes separation blood
It is chilly to hide standby.Take after blood and to dissect mouse, press from both sides out spleen with tweezers, claim its quality, record data.By kit each component
Taken out from box, balance to room temperature（18~25 DEG C）.Superoxide dismutase is determined using xanthine oxidase（SOD）It is living
Property；Catalase（CAT）The measuring principle of activity is the reaction of catalase breaks hydrogen peroxide by adding ammonium molybdate
Rapid to stop, remaining hydrogen peroxide produces flaxen complex compound with ammonium molybdate, and its variable quantity is determined at 405nm, can be counted
Calculate CAT vigor；Lactic dehydrogenase（LDH）Determination of activity is then by using pyruvic acid and 2,4 dinitrophenyl hydrazine reaction generation third
Ketone acid dinitrophenylhydrazone, it shows brownish red in the basic conditions, therefore can be tried to achieve by colorimetric method；Immunoturbidimetry determines complement
C3, C4 content.Turbidimetry for Determination lysozyme（LZM）Content.Operation is strictly carried out by each kit specification.
4.3 experimental result
4.3.1 immune organ index and spleen index
As shown in Figure 5, index and spleen index increases after mouse administration lentinan, inorganic chromium, lentinan-Cr complexs,
And administration lentinan-Cr complexs high dose or middle dosage after, index and spleen index apparently higher than administration physiological saline mouse,
Relatively administration lentinan, the mouse of inorganic chromium are also obviously improved.
4.3.2 superoxide dismutase（SOD）Vitality test
Fig. 6 understood, mouse administration lentinan, inorganic chromium, and SOD vigor has been carried in serum after lentinan-Cr complexs
After height, and administration lentinan-Cr complexs high dose or middle dosage, SOD vigor is given birth to apparently higher than administration in mice serum
The mouse of salt solution, relatively administration lentinan, the mouse of inorganic chromium is managed to be also obviously improved.
4.3.3 lactic dehydrogenase（LDH）Vitality test
Fig. 7 understood, mouse administration lentinan, inorganic chromium, and LDH activity has been carried in serum after lentinan-Cr complexs
After height, and administration lentinan-Cr complexs middle dosage or low dosage, LDH activity is given birth to apparently higher than administration in mice serum
The mouse of salt solution, relatively administration lentinan, the mouse of inorganic chromium is managed to be also obviously improved.
4.3.4 catalase (CAT) vitality test
Fig. 8 understood, mouse administration lentinan, inorganic chromium, and CAT vigor has been carried in serum after lentinan-Cr complexs
CAT vigor is above administration perfume in height, and the experimental mice serum of the administration high, medium and low dosage of lentinan-Cr complexs
CAT vigor in mushroom polysaccharide and inorganic chromium mice serum.
4.3.5 lysozyme（LZM）Assay
Fig. 9 understands, mouse administration lentinan, inorganic chromium, and lysozyme content has been in serum after lentinan-Cr complexs
Improve, and administration lentinan-Cr complexs high dose or middle dosage after, in mice serum lysozyme content apparently higher than to
The mouse of medicine physiological saline, relatively administration lentinan, the mouse of inorganic chromium are also obviously improved.
4.3.6 Complement C_3, C4 assays
Table 1：Lentinan-Cr complexs are to Complement C_3 in mice serum, the influence of C4 contents
As shown in Table 1, Complement C_3, C4 contents in serum is administered after lentinan, inorganic chromium, lentinan-Cr complexs in mouse
Increase, and administration the high, medium and low dosage of lentinan-Cr complexs after, in mice serum Complement C_3, C4 contents compared with
Administration lentinan, inorganic chromium increase.
5 conclusions
By immunological regulation and the anti-oxidant experimental result of lentinan-Cr complexs it could be assumed that, a certain amount of mushroom is administered
Polysaccharide-Cr complexs can improve the immunity and oxidation resistance of mouse.
The foregoing is only presently preferred embodiments of the present invention, all equivalent changes done according to scope of the present invention patent with
Modification, should all belong to the covering scope of the present invention.
Claims (3)
1. a kind of preparation method of lentinan-chromic compound, it is characterised in that：Lentinan is coordinated under certain condition with chromium
Reaction forms complex, specifically includes following steps：
（1）The purifying of lentinan
The thick lentinans of 10.0g are weighed in 800mL distilled water, simultaneously 2 mol L are added dropwise in 80 DEG C of heating water baths-1NaOH solution, control
PH=8.0 of solution processed, stirring accelerates the dissolving of Thick many candies, then thick lentinan liquid by volume：Chloroform：N-butanol=25：
5:1 adds chloroform and n-butanol, quickly stirs 20min, stands, and point liquid removes sub-cloud organic reagent, is then centrifuged in the middle of removing
Protein solid；Thick lentinan liquid by volume again：Chloroform：N-butanol=25：5:1 adds more than chloroform and n-butanol, repetition
Operation, until middle produce without white solid, supernatant rotary evaporation is concentrated into the 1/5 of original volume, adds 2-3 times of volume
95wt% ethanol alcohol precipitations, centrifugation, take pellet frozen dry lentinan after purification；
（2）The preparation and purification of lentinan-chromic compound
The lentinan that 1.6g is purified and dried is weighed, is dissolved by heating in 250mL80 DEG C of distilled water, in 80 DEG C of water bath conditions
Under 2 mol L are slowly added dropwise-1CrCl3•6H2O solution and 2 mol L-1NaOH solution and be stirred continuously, control pH value of solution
=9.0, until occurring flocculent deposit in solution, stop that CrCl is added dropwise3•6H2O and NaOH solution, continue to keep 80 DEG C of heating water baths
1h, 3500r/min centrifugation 10min take supernatant, add the 95wt% ethanol of 2-3 times of volume, cooling and standings are collected by centrifugation heavy
Form sediment, swung with 95wt% ethanol, absolute ethyl alcohol, acetone, absolute ether stirring respectively and washed sediment, be collected by centrifugation and precipitate and depressurize dry
It is dry, obtain lentinan-chromic compound crude product；
Lentinan-chromic compound crude product is dissolved in appropriate distilled water, is fitted into bag filter and is clamped, and is added water in 2L large beakers,
Magnetic agitation is dialysed 2-3 days, and a water is changed in centre at regular intervals, changes water frequency first quick and back slow, after dialysis terminates, concentration,
2-3 times of volume 95wt% ethanol is added, precipitation is collected by centrifugation, precipitation uses 95wt% ethanol respectively, absolute ethyl alcohol, acetone, anhydrous
Ether is washed, and is dried under reduced pressure, is obtained lentinan-chromic compound fine work.
2. lentinan-chromic compound made from preparation method as claimed in claim 1, it is characterised in that：Lentinan-chromium
The content of Cr elements is 6.27wt% in complex.
3. lentinan-chromic compound as claimed in claim 2 is preparing immunomodulator, oxidation resistant medicine or health care food
Application in product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710623831.8A CN107312108A (en) | 2017-07-27 | 2017-07-27 | A kind of preparation method and applications of lentinan chromic compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710623831.8A CN107312108A (en) | 2017-07-27 | 2017-07-27 | A kind of preparation method and applications of lentinan chromic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107312108A true CN107312108A (en) | 2017-11-03 |
Family
ID=60169863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710623831.8A Pending CN107312108A (en) | 2017-07-27 | 2017-07-27 | A kind of preparation method and applications of lentinan chromic compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107312108A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109879980A (en) * | 2019-03-06 | 2019-06-14 | 武汉轻工大学 | A kind of preparation method and antioxidant of rice bran polysaccharide metal complex |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4640358A (en) * | 1984-03-26 | 1987-02-03 | Mobil Oil Corporation | Oil recovery process employing a complexed polysaccharide |
| CN102964459A (en) * | 2012-11-02 | 2013-03-13 | 华南理工大学 | Lentinan calcium complex, and preparation method and application thereof |
| CN103193894A (en) * | 2013-04-25 | 2013-07-10 | 河南中医学院 | Preparation method and application of honeysuckle stem polysaccharide chromium complex |
| CN103724447A (en) * | 2013-12-31 | 2014-04-16 | 中国科学院长春应用化学研究所 | Extraction and classification method of lentinan |
-
2017
- 2017-07-27 CN CN201710623831.8A patent/CN107312108A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4640358A (en) * | 1984-03-26 | 1987-02-03 | Mobil Oil Corporation | Oil recovery process employing a complexed polysaccharide |
| CN102964459A (en) * | 2012-11-02 | 2013-03-13 | 华南理工大学 | Lentinan calcium complex, and preparation method and application thereof |
| CN103193894A (en) * | 2013-04-25 | 2013-07-10 | 河南中医学院 | Preparation method and application of honeysuckle stem polysaccharide chromium complex |
| CN103724447A (en) * | 2013-12-31 | 2014-04-16 | 中国科学院长春应用化学研究所 | Extraction and classification method of lentinan |
Non-Patent Citations (2)
| Title |
|---|
| CONG WANG等: "Anti-diabetic effects of Inonotus obliquus polysaccharides-chromium(III) complex in type 2 diabetic mice and its sub-acute toxicity evaluation in normal mice", 《FOOD AND CHEMICAL TOXICOLOGY》 * |
| 张虎成等主编: "《发酵原料药生产（第1版）》", 31 May 2014, 中国轻工业出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109879980A (en) * | 2019-03-06 | 2019-06-14 | 武汉轻工大学 | A kind of preparation method and antioxidant of rice bran polysaccharide metal complex |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lakhanpal et al. | Medicinal and nutraceutical genetic resources of mushrooms | |
| Gao et al. | Characteristic anti-inflammatory and antioxidative effects of enzymatic-and acidic-hydrolysed mycelium polysaccharides by Oudemansiella radicata on LPS-induced lung injury | |
| CN103804509B (en) | A kind of selenizing algal polysaccharides preparation method of high bioactivity | |
| CN102276753B (en) | Method for preparing polyporus selenium polysaccharide | |
| CN104277134B (en) | A kind of preparation method and applications of the dictyophora fungus polysaccharide-chelates of zinc with anti-tumor activity | |
| CN103880910B (en) | A kind of preparation method and its usage of Cyclosiversigenin | |
| CN106212046A (en) | A kind of Ganoderma breeding method and the method for manufactured meat Ganoderma water | |
| Dong et al. | Preparation, characterization and bioactivities of Athelia rolfsii exopolysaccharide-zinc complex (AEPS-zinc) | |
| CN105153319B (en) | A kind of application of sealwort paragalactan and preparation method thereof and anti-inflammatory aspect | |
| CN101104646A (en) | Preparation method for eucheuma gelatinae polysaccharide selenide and application | |
| CN109608557A (en) | Polysaccharides extracts Isolation and purification method, Lycium chinense glycopeptide and preparation method | |
| CN104877035A (en) | Preparation method of auricularia polysaccharide with hypoglycemic effect | |
| CN105985451B (en) | A kind of Radix Angelicae Sinensis acidity polysaccharide component and its extracting method and application | |
| CN107286267A (en) | One Polysaccharides From Laminaria Japonica Zn complex and its preparation and application | |
| CN107312108A (en) | A kind of preparation method and applications of lentinan chromic compound | |
| Ng et al. | Chemical structures, extraction and analysis technologies, and bioactivities of edible fungal polysaccharides from Poria cocos: An updated review | |
| CN108079010A (en) | Chestnut polysaccharide pharmaceutical composition with antitumaous effect and preparation method thereof | |
| CN104666842B (en) | One seed ginseng stilbene monkey mushroom health products and preparation method thereof | |
| WO2009102008A1 (en) | Low-molecular-weight substance derived from maitake mushroom and having immunostimulating activity and anti-tumor activity | |
| CN102225198B (en) | Anti-tumour medicine composition and preparation method and application thereof | |
| CN108409621A (en) | A kind of dihydromyricetin selenium compound for treating liver cancer and related liver disease | |
| CN105399794B (en) | Fructus momordicae triterpene saponin and salt thereof, preparation method and applications of fructus momordicae triterpene saponin and salt thereof, and pharmaceutical composition containing fructus momordicae triterpene saponin and salt thereof | |
| CN107880147A (en) | Chinese chestnut active anticancer polysaccharide and its isolation and purification method | |
| CN106589154B (en) | A kind of preparation method of open country watermelon selenium polysaccharide | |
| CN105859820B (en) | Folic acid parcel neocholan polyoxomolybdate pyrene hybrid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171103 |